WhiteFiber (NASDAQ:WYFI – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research note issued on Thursday, Benzinga reports. They currently have a $37.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 113.75% from the company’s current price. Several other equities […]

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued on Thursday, Benzinga reports. They presently have a $120.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 30.96% from the company’s current price. Other research analysts have […]

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $120.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 56.72% from the stock’s previous close. Other […]

Cytokinetics (NASDAQ:CYTK – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $140.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 94.20% from the stock’s previous close. […]

Sagimet Biosciences (NASDAQ:SGMT – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $29.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 181.96% from the company’s current price. A […]

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $95.00 target price on the biotechnology company’s stock. HC Wainwright’s price target would suggest a potential upside of 66.73% from the stock’s current price. Other equities […]